Search results
Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial
Digital Journal· 6 days agoAcasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high</ ...
The $500,000 penalty for working moms: New study shows how much having a child can cost women over...
Fortune via Yahoo Finance Canada· 6 days agoMeanwhile, Princeton University and the London School of Economics collected data from 134 countries...